Document is current
Any future updates will be listed below
-
Authors
Lorenzo, Nuria L.
Eraña, Hasier
Vidal, Enric
Charco, Jorge M.
Parga, Lucía
Díaz-Domínguez, Carlos M.
Veiga, Sonia
Bravo, Susana
Giler, Samanta
Geijo, Mariví
Requena, Jesús R.
Castilla, Joaquín
-
Funding
Funding for this research was provided by:
Regional Development Funds, European Union (EFA031/01 (NEURO-COOP), EFA031/01 (NEURO-COOP), EFA031/01 (NEURO-COOP))
Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, Spain (PID2021-1222010B-C22, PID2020-117465GB-I00)
Ministerio de Ciencia e Innovación, Agencia estatal de Investigación, Spain (PID2021-122201OB-C21)
Joint Program in Neurodegenerative Research, JPND, European Union (JPND-2021-650-130)
Instituto de Salud Carlos III (AC21_2/00024)
Ministerio de Ciencia e Innovación (CEX2021-001136-S)
- License Information
-
More Information
Article History
Received: 12 June 2025
Accepted: 23 October 2025
First Online: 3 December 2025
Declarations
:
: Mouse experiments were performed at multiple research facilities: CIC bioGUNE, Centro de Biomedicina Experimental (CEBEGA) of the University of Santiago de Compostela, Neiker—Basque Institute for Agricultural Research and Development, and IRTA-CReSA Animal Health Research Center. These procedures were approved by the respective institutional ethics committees with the following project codes: CIC bioGUNE (P-CBG-CBBA-0314 and 15,005/16/006), CEBEGA (15012/2023/002), Neiker (NEIKER-OEBA-2021-003), and IRTA-CReSA (5767, 11926 and 1124M2R). All experimental procedures performed until 2013 in Spain complied with the “Real Decreto 1201/2005 de 10 de Octubre” and “Real Decreto 214/1997 de 30 de Julio” on animal protection for experimental purposes, and those carried out from 2013 onwards complied with “Real Decreto 53/2013 de 1 de febrero” on protection of animals used for experimentation and other scientific purposes, which is based on European Directive 2010/63/EU on Laboratory Animal Protection.
: Authors H.E. and J.M.C. are employed by the commercial company ATLAS Molecular Pharma SL. This does not alter our adherence to the Journal’s policies on sharing data and materials and did not influence in any way the work reported in this manuscript, given that the company had no role in study design, funding, and data analysis. The rest of the authors declare no competing interests.
